Belhaven Biopharma

Series-A
belhavenbio.com Biotech & Healthcare
Total Funding $10M
Latest Round $10M Series-A
Last Announced Aug 19, 2025
Investors Undisclosed
Decision Makers 6 Verified

About Belhaven Biopharma

Discover Belhaven Bio's needle-free Epipen alternative, fast-acting nasal medication for those with a fear of needles. Safe, allergy relief without injections

Sectors & Market Categories

Company Details

Intelligence Dossier

Corporate & Operational Profile

Primary Industry Biotech & Healthcare
Funding Stage Series-A
Global Headquarters Undisclosed
Tracked Since Oct 1, 2026

Web & Domain Identity

Official Website belhavenbio.com
Domain Registered Date Aug 12, 2020

Social & Network Presence

X / Twitter Profile Not linked
LinkedIn Corporate Not linked

Company Milestones & Timeline

3 Events
  1. Capital Raise

    Raised $10,000,000 · Series-A

    startupintros.com

  2. Capital Raise

    Seed announced

    fundraisingfox.com

  3. Milestone

    Website domain registered

    belhavenbio.com

Investors & Backers

Investor firms and individual backers were not publicly disclosed in available round filings for Belhaven Biopharma.

Funding History

2 Rounds
Series-A · Aug 19, 2025
Seed · Jan 21, 2025

Press Coverage & Sources

Recently Funded Biotech & Healthcare Startups

View all

Search the startup feeds free with 50 starter credits.

START FREE WITH 50 CREDITS
Recently funded startups
New SaaS launches
Never pay twice for contacts